2,071 reports of this reaction
1.5% of all DROSPIRENONE AND ETHINYL ESTRADIOL reports
#15 most reported adverse reaction
THROMBOSIS is the #15 most commonly reported adverse reaction for DROSPIRENONE AND ETHINYL ESTRADIOL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 2,071 FDA adverse event reports linking DROSPIRENONE AND ETHINYL ESTRADIOL to THROMBOSIS. This represents approximately 1.5% of all 140,358 adverse event reports for this drug.
Patients taking DROSPIRENONE AND ETHINYL ESTRADIOL who experience thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOSIS is a less commonly reported adverse event for DROSPIRENONE AND ETHINYL ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to thrombosis, the following adverse reactions have been reported for DROSPIRENONE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to thrombosis in FDA adverse event reports:
THROMBOSIS has been reported as an adverse event in 2,071 FDA reports for DROSPIRENONE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOSIS accounts for approximately 1.5% of all adverse event reports for DROSPIRENONE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience thrombosis while taking DROSPIRENONE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.